128 related articles for article (PubMed ID: 15234567)
1. Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old.
Parmar S; Rundhaugen LM; Boehlke L; Riley M; Nabhan C; Raji A; Frater JL; Tallman MS
Leuk Res; 2004 Sep; 28(9):909-19. PubMed ID: 15234567
[TBL] [Abstract][Full Text] [Related]
2. Increased cellular glutathione and protection by bone marrow stromal cells account for the resistance of non-acute promylocytic leukemia acute myeloid leukemia cells to arsenic trioxide in vivo.
Lee C; Lin Y; Huang M; Lin C; Liu C; Chow J; Liu HE
Leuk Lymphoma; 2006 Mar; 47(3):521-9. PubMed ID: 16396776
[TBL] [Abstract][Full Text] [Related]
3. A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia.
Sekeres MA; Maciejewski JP; Erba HP; Afable M; Englehaupt R; Sobecks R; Advani A; Seel S; Chan J; Kalaycio ME
Cancer; 2011 Mar; 117(6):1253-61. PubMed ID: 20960521
[TBL] [Abstract][Full Text] [Related]
4. Adding ascorbic acid to arsenic trioxide produces limited benefit in patients with acute myeloid leukemia excluding acute promyelocytic leukemia.
Aldoss I; Mark L; Vrona J; Ramezani L; Weitz I; Mohrbacher AM; Douer D
Ann Hematol; 2014 Nov; 93(11):1839-43. PubMed ID: 24906216
[TBL] [Abstract][Full Text] [Related]
5. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
Thirugnanam R; George B; Chendamarai E; Lakshmi KM; Balasubramanian P; Viswabandya A; Srivastava A; Chandy M; Mathews V
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309
[TBL] [Abstract][Full Text] [Related]
6. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: a bridge to transplantation.
Leoni F; Gianfaldoni G; Annunziata M; Fanci R; Ciolli S; Nozzoli C; Ferrara F
Haematologica; 2002 May; 87(5):485-9. PubMed ID: 12010661
[TBL] [Abstract][Full Text] [Related]
7. Arsenic trioxide in hematological malignancies: the new discovery of an ancient drug.
Bonati A; Rizzoli V; Lunghi P
Curr Pharm Biotechnol; 2006 Dec; 7(6):397-405. PubMed ID: 17168655
[TBL] [Abstract][Full Text] [Related]
8. Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy.
Cicconi L; Breccia M; Franceschini L; Latagliata R; Molica M; Divona M; Diverio D; Rizzo M; Ottone T; Iaccarino L; Alfonso V; Foa R; Voso MT; Lo-Coco F
Ann Hematol; 2018 Oct; 97(10):1797-1802. PubMed ID: 29951912
[TBL] [Abstract][Full Text] [Related]
9. Arsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: updated outcomes of the phase II study and postremission therapies.
Shigeno K; Naito K; Sahara N; Kobayashi M; Nakamura S; Fujisawa S; Shinjo K; Takeshita A; Ohno R; Ohnishi K
Int J Hematol; 2005 Oct; 82(3):224-9. PubMed ID: 16207595
[TBL] [Abstract][Full Text] [Related]
10. Outcomes and prognostic factors of first relapsed acute promyelocytic leukemia patients undergoing salvage therapy with intravenous arsenic trioxide and chemotherapy.
Lou Y; Suo S; Tong Y; Tong H; Qian W; Meng H; Mai W; Huang J; Yu W; Jin J
Ann Hematol; 2014 Jun; 93(6):941-8. PubMed ID: 24408159
[TBL] [Abstract][Full Text] [Related]
11. Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia.
Roboz GJ; Ritchie EK; Curcio T; Provenzano J; Carlin R; Samuel M; Wittenberg B; Mazumdar M; Christos PJ; Mathew S; Allen-Bard S; Feldman EJ
Cancer; 2008 Nov; 113(9):2504-11. PubMed ID: 18825661
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy with arsenic trioxide for hematological malignancies.
Takahashi S
Anticancer Agents Med Chem; 2010 Jul; 10(6):504-10. PubMed ID: 20812901
[TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia.
Lou Y; Qian W; Meng H; Mai W; Tong H; Tong Y; Huang J; Jin J
Hematol Oncol; 2014 Mar; 32(1):40-6. PubMed ID: 23963734
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of 5-fluorouracil/leucovorin and arsenic trioxide for patients with refractory/relapsed colorectal carcinoma.
Ardalan B; Subbarayan PR; Ramos Y; Gonzalez M; Fernandez A; Mezentsev D; Reis I; Duncan R; Podolsky L; Lee K; Lima M; Ganjei-Azar P
Clin Cancer Res; 2010 Jun; 16(11):3019-27. PubMed ID: 20501625
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma.
Hermine O; Dombret H; Poupon J; Arnulf B; Lefrère F; Rousselot P; Damaj G; Delarue R; Fermand JP; Brouet JC; Degos L; Varet B; de Thé H; Bazarbachi A
Hematol J; 2004; 5(2):130-4. PubMed ID: 15048063
[TBL] [Abstract][Full Text] [Related]
16. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.
Smith BD; Levis M; Beran M; Giles F; Kantarjian H; Berg K; Murphy KM; Dauses T; Allebach J; Small D
Blood; 2004 May; 103(10):3669-76. PubMed ID: 14726387
[TBL] [Abstract][Full Text] [Related]
17. Homoharringtonine potentiates the antileukemic activity of arsenic trioxide against acute myeloid leukemia cells.
Chen P; Zhan W; Wang B; You P; Jin Q; Hou D; Wang X; You R; Zou H; Chen Y; Huang H
Exp Cell Res; 2019 Mar; 376(2):114-123. PubMed ID: 30763586
[TBL] [Abstract][Full Text] [Related]
18. Economic evaluation of arsenic trioxide compared to all-trans retinoic acid + conventional chemotherapy for treatment of relapsed acute promyelocytic leukemia in Canada.
Lachaine J; Mathurin K; Barakat S; Couban S
Eur J Haematol; 2015 Sep; 95(3):218-29. PubMed ID: 25354894
[TBL] [Abstract][Full Text] [Related]
19. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia.
Estey E; Garcia-Manero G; Ferrajoli A; Faderl S; Verstovsek S; Jones D; Kantarjian H
Blood; 2006 May; 107(9):3469-73. PubMed ID: 16373661
[TBL] [Abstract][Full Text] [Related]
20. Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia.
Zhou J; Zhang Y; Li J; Li X; Hou J; Zhao Y; Liu X; Han X; Hu L; Wang S; Zhao Y; Zhang Y; Fan S; Lv C; Li L; Zhu L
Blood; 2010 Mar; 115(9):1697-702. PubMed ID: 20029047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]